NCT03172975View on ClinicalTrials.gov

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

January 30, 2025

Conditions
Hookworm Infections
Interventions
BIOLOGICAL

Na-GST-1/Alhydrogel

Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel

BIOLOGICAL

Na-GST-1/Alhydrogel + CPG 10104

Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide

BIOLOGICAL

Na-GST-1/Alhydrogel + GLA-AF

Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)

BIOLOGICAL

Placebo

Physiological sterile saline solution

DRUG

Albendazole

Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

OTHER

Necator americanus Larval Inoculum

50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Trial Locations (1)

20037

George Washington University, Washington D.C.

All Listed Sponsors
collaborator

George Washington University

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Baylor College of Medicine

OTHER

NCT03172975 - Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection | Biotech Hunter | Biotech Hunter